Free
Education  |   June 2004
Production of Paradoxical Sensory Hypersensitivity by α2-Adrenoreceptor Agonists
Author Affiliations & Notes
  • Aline Quartilho, B.S.
    *
  • Heriberto P. Mata, B.S.
  • Mohab M. Ibrahim, M.S.
    *
  • Todd W. Vanderah, Ph.D.
  • Michael H. Ossipov, Ph.D.
    §
  • Josephine Lai, Ph.D.
    ||
  • Frank Porreca, Ph.D.
    #
  • T. Philip Malan, Ph.D., M.D.
    #
  • * Graduate Student, Interdisciplinary Graduate Program in Pharmacology and Toxicology, † Research Specialist, Department of Anesthesiology, ‡ Assistant Professor, # Professor, Departments of Anesthesiology and Pharmacology, § Research Associate Professor, || Professor, Department of Pharmacology, The University of Arizona.
Article Information
Education
Education   |   June 2004
Production of Paradoxical Sensory Hypersensitivity by α2-Adrenoreceptor Agonists
Anesthesiology 6 2004, Vol.100, 1538-1544. doi:
Anesthesiology 6 2004, Vol.100, 1538-1544. doi:
α2-ADRENORECEPTOR–selective agonists are administered both acutely and chronically for a variety of indications. 1,2 Many of the acute uses of α2-receptor agonists occur at the time of surgery. 2 They decrease the amount of general anesthetic agents required, provide sedation, decrease hemodynamic fluctuations caused by anesthesia and surgery, prevent postoperative shivering, and may decrease perioperative myocardial ischemia. In addition, because of their analgesic properties, they may improve postoperative pain control and decrease the amount of other analgesic agents (e.g.  , opioids) needed.
The α2-receptor agonist clonidine is also administered systemically or perispinally for the treatment of chronic pain. 1 Although epidural administration for the treatment of cancer pain is the only pain application approved by the US Food and Drug Administration, clonidine has been administered orally, transdermally, and intrathecally for the treatment of pain syndromes of both malignant and benign causes. Clonidine has also been used chronically for the treatment of hypertension, congestive heart failure, and ischemic heart disease.
We hypothesized that α2-receptor agonists would produce sensory hypersensitivity based on comparison with μ-opioid receptor systems. Prolonged or repeated administration of α2-receptor agonists results in antinociceptive tolerance. 3–5 Antinociceptive tolerance to opioids has been hypothesized to result from a decrease in nociceptive threshold, leading to an increase in the dose of drug required to overcome this increased pain sensitivity. 6,7 Therefore, we hypothesized that α2-adrenoreceptor agonists might also produce a paradoxical decrease in nociceptive thresholds. This work was also performed in light of the observation by Takano and Yaksh 4 that continuous intrathecal infusion of α2-receptor agonists produced touch-evoked allodynia.
Materials and Methods
Animals
Approval was obtained from the University of Arizona Animal Care and Use Committee (Tucson, Arizona). Male Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN) weighed 200–300 g at the time of testing. They were allowed food and water ad libitum  and were maintained in a climate-controlled room on a 12-h light/dark cycle. All animal procedures conformed to the guidelines of the National Institutes of Health and the International Association for the Study of Pain.
Intrathecal Catheter Implantation
Rats were chronically implanted with intrathecal catheters as described by Yaksh and Rudy. 8 Rats were anesthetized with halothane and placed in a stereotactic head holder. The occipital muscles were separated from their insertion on the skull and retracted caudally to expose the cisternal membrane. The membrane was incised, and polyethylene tubing was passed caudally from the cisterna magna to the level of the lumbar enlargement. Animals with evidence of neurologic deficits (< 1%) were promptly euthanized. Intrathecal drug administration was performed by delivering the drug in a volume of 5 μl, followed by a 9-μl saline flush.
Prolonged Infusion Using Osmotic Minipumps
Prolonged infusions were performed using osmotic minipumps (model 2001; Alza, Mountain View, CA). For subcutaneous infusion, a small incision was made in the skin between the scapulae. A small pocket was formed in the subcutaneous connective tissue, and the minipumps were placed in the pocket, with the flow moderator pointing away from the incision. For spinal infusions, minipumps were attached to the indwelling intrathecal catheters and placed in subcutaneous pockets. Skin incisions were sutured closed. For intrathecal bolus injection of drugs after intrathecal clonidine infusion, animals were anesthetized with halothane, the intrathecal catheter was exteriorized, the minipump was disconnected, and drugs were injected through the catheter in a volume of 5 μl followed by a 9-μl saline flush.
Drugs
Clonidine was obtained from Tocris (Ellisville, MO). Idazoxan hydrochloride and (+)-MK-801 were obtained from Sigma (St. Louis, MO). Antiserum to dynorphin A (1–17) was obtained from Bachem/Peninsula Laboratories (San Carlos, CA). This rabbit antiserum was 100% cross-reactive with dynorphin (1–13) and dynorphin (1–8).
Assessment of Mechanical Sensitivity
Rats were allowed to acclimate for 30 min within Plexiglas®enclosures with wire mesh bottoms. Paw withdrawal thresholds were determined in response to probing of the hind paw with a series of calibrated von Frey filaments applied perpendicularly to the plantar surface of the paw. A maximal cutoff of 15 g was used because larger filaments lifted the paw even if the animal did not actively withdraw. Data were analyzed by the up-and-down method of Dixon, as described by Chaplan et al.  9 
Assessment of Thermal Sensitivity
Thermal sensitivity was assessed as described by Hargreaves et al.  10 Rats were allowed to acclimate within Plexiglas®enclosures on a clear glass plate maintained at 30°C. A radiant heat source was focused onto the plantar surface of the hind paw. The stimulus and the timer were both interrupted when withdrawal of the hind paw was detected by a photodetection device. A maximal cutoff of 40 s was used to prevent tissue damage.
Dynorphin Immunoassay
Rats were deeply anesthetized with ether and decapitated. Transverse incisions were made into the upper cervical and the sacral spinal column. The spinal cord was ejected using ice-cold saline and placed on a glass Petri dish that was resting on ice. The lumbar spinal cord was rapidly dissected, and the dorsal spinal cord was dissected from the ventral spinal cord at the level of the central canal. Tissue samples of dorsal spinal cord were rapidly frozen on dry ice and stored at −70°C. For immunoassay, thawed tissue was placed in 1 N acetic acid, disrupted with a Polytron homogenizer (Polytron Corp., Elkhart, IN), and incubated for 20 min at 95°C. After centrifugation at 10,000 g  for 20 min (4°C), the supernatant was lyophilized and stored at −70°C. The lyophilized supernatant was dissolved in water, and protein concentrations were determined using the bicinchoninic acid method with bovine serum albumin as a standard. Immunoassay was performed using a commercial immunoassay kit with an antibody specific for dynorphin A (1–17) (Bachem/Peninsula Laboratories).
Statistical Analysis
The assessment of time effects of drugs and individual group comparisons were performed using one-way and two-way analyses of variance. Post hoc  analyses were performed using the Dunnett test when posttreatment values were compared with baseline values and using the Student t  test when different treatment groups were compared. When only two treatment groups were compared, the Student t  test was used. Differences with P  < 0.05 were considered significant.
Results
A single systemic injection of the α2-adrenoreceptor–selective agonist clonidine (1.2 mg/kg subcutaneous) resulted in transient antinociception to a thermal stimulus followed by delayed thermal hypersensitivity 24–30 h after clonidine injection (fig. 1A). Both the antinociception and the thermal hypersensitivity were prevented by coadministration of the α2-adrenoreceptor–selective antagonist idazoxan (3 mg/kg subcutaneous, 10 min before clonidine and every 2 h for three doses). MK-801 (0.15 mg/kg subcutaneous, 10 min before clonidine) prevented clonidine-induced thermal hypersensitivity. The effects of MK-801 on the antinociceptive phase were not tested because of concerns regarding centrally mediated behavioral effects of MK-801 in the first few hours after systemic administration. Similarly, a single subcutaneous injection of clonidine (1.2 mg/kg) resulted in delayed tactile hypersensitivity 24–34 h after clonidine administration (fig. 1B). A single subcutaneous injection of clonidine resulted in tactile and thermal hypersensitivity 24 h after clonidine administration if sensory testing was not performed in the intervening time period, demonstrating that the observed sensory hypersensitivity was not due to repeated sensory testing (thermal withdrawal latency 24 h after vehicle [saline] injection = 21.5 ± 0.4 s [mean ± SEM], withdrawal latency 24 h after clonidine injection = 16 ± 1 s [P  < 0.05]; tactile withdrawal threshold 24 h after vehicle [saline] injection = 13 ± 1 g, withdrawal threshold 24 h after clonidine injection = 2.9 ± 0.7 g [P  < 0.05]).
Fig. 1. A single dose of α2-adrenoreceptor–selective agonist produces antinociception followed by sensory hypersensitivity. (A  ) Antinociception and thermal hypersensitivity produced by systemic (subcutaneous) clonidine (CLN). (B  ) Tactile hypersensitivity produced by systemic subcutaneous clonidine. (C  ) Antinociception and thermal hypersensitivity produced by spinal (intrathecal) clonidine. (D  ) Antinociception and thermal hypersensitivity produced by intrathecal dexmedetomidine (DEX). Where tested, the α2-adrenoreceptor–selective antagonist idazoxan (IDAZ) prevented the production of antinociception and thermal hypersensitivity. Where tested, the N  -methyl-d-aspartate receptor antagonist MK-801 prevented the production of thermal hypersensitivity. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control.
Fig. 1. A single dose of α2-adrenoreceptor–selective agonist produces antinociception followed by sensory hypersensitivity. (A 
	) Antinociception and thermal hypersensitivity produced by systemic (subcutaneous) clonidine (CLN). (B 
	) Tactile hypersensitivity produced by systemic subcutaneous clonidine. (C 
	) Antinociception and thermal hypersensitivity produced by spinal (intrathecal) clonidine. (D 
	) Antinociception and thermal hypersensitivity produced by intrathecal dexmedetomidine (DEX). Where tested, the α2-adrenoreceptor–selective antagonist idazoxan (IDAZ) prevented the production of antinociception and thermal hypersensitivity. Where tested, the N 
	-methyl-d-aspartate receptor antagonist MK-801 prevented the production of thermal hypersensitivity. Data are expressed as mean ± SEM; n = 6 per group. *P 
	< 0.05 compared with vehicle control.
Fig. 1. A single dose of α2-adrenoreceptor–selective agonist produces antinociception followed by sensory hypersensitivity. (A  ) Antinociception and thermal hypersensitivity produced by systemic (subcutaneous) clonidine (CLN). (B  ) Tactile hypersensitivity produced by systemic subcutaneous clonidine. (C  ) Antinociception and thermal hypersensitivity produced by spinal (intrathecal) clonidine. (D  ) Antinociception and thermal hypersensitivity produced by intrathecal dexmedetomidine (DEX). Where tested, the α2-adrenoreceptor–selective antagonist idazoxan (IDAZ) prevented the production of antinociception and thermal hypersensitivity. Where tested, the N  -methyl-d-aspartate receptor antagonist MK-801 prevented the production of thermal hypersensitivity. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control.
×
A single intrathecal injection of clonidine (300 μg) resulted in transient antinociception to a thermal stimulus, followed by delayed thermal hypersensitivity 24 h after clonidine injection (fig. 1C). These effects were prevented by coadministration of idazoxan (150 μg intrathecal, 10 min before clonidine). MK-801 (3.4 μg intrathecal, 10 min before clonidine) did not affect the antinociceptive phase but did prevent the thermal hypersensitivity. Similarly, a single intrathecal injection of the α2-adrenoreceptor–selective agonist dexmedetomidine (30 μg) resulted in transient antinociception to a thermal stimulus, followed by delayed thermal hypersensitivity 26–28 h after dexmedetomidine injection (fig. 1D).
Intrathecal MK-801 (3.4 μg) reversed the thermal hypersensitivity produced by a single dose of intrathecal clonidine (300 μg) when administered 24 h later (fig. 2).
Fig. 2. Intrathecal MK-801 reverses the thermal hypersensitivity produced by a single dose of intrathecal clonidine (CLN). MK-801 was administered 24 h after clonidine. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control. #P  < 0.05 compared with clonidine alone.
Fig. 2. Intrathecal MK-801 reverses the thermal hypersensitivity produced by a single dose of intrathecal clonidine (CLN). MK-801 was administered 24 h after clonidine. Data are expressed as mean ± SEM; n = 6 per group. *P 
	< 0.05 compared with vehicle control. #P 
	< 0.05 compared with clonidine alone.
Fig. 2. Intrathecal MK-801 reverses the thermal hypersensitivity produced by a single dose of intrathecal clonidine (CLN). MK-801 was administered 24 h after clonidine. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control. #P  < 0.05 compared with clonidine alone.
×
Continuous systemic infusion of clonidine (10 μg/h subcutaneous) resulted in thermal hypersensitivity 2 days after initiation of the infusion (fig. 3A) and tactile hypersensitivity 1 day after initiation of the infusion (fig. 3B). This sensory hypersensitivity was completely prevented by coinfusion of idazoxan (200 μg/h subcutaneous) using a second minipump.
Fig. 3. Prolonged (5-day) infusions of clonidine (CLN) produce sensory hypersensitivity. (A  ) Production of thermal hypersensitivity by subcutaneous clonidine. (B  ) Production of tactile hypersensitivity by subcutaneous clonidine. (C  ) Production of thermal hypersensitivity by intrathecal clonidine. (D  ) Production of tactile hypersensitivity by intrathecal clonidine. Coinfusion of the α2-adrenoreceptor–selective antagonist idazoxan (IDAZ) prevented the production of thermal and tactile hypersensitivity. Where tested, the N  -methyl-d-aspartate receptor antagonist MK-801 prevented the production of sensory hypersensitivity. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control.
Fig. 3. Prolonged (5-day) infusions of clonidine (CLN) produce sensory hypersensitivity. (A 
	) Production of thermal hypersensitivity by subcutaneous clonidine. (B 
	) Production of tactile hypersensitivity by subcutaneous clonidine. (C 
	) Production of thermal hypersensitivity by intrathecal clonidine. (D 
	) Production of tactile hypersensitivity by intrathecal clonidine. Coinfusion of the α2-adrenoreceptor–selective antagonist idazoxan (IDAZ) prevented the production of thermal and tactile hypersensitivity. Where tested, the N 
	-methyl-d-aspartate receptor antagonist MK-801 prevented the production of sensory hypersensitivity. Data are expressed as mean ± SEM; n = 6 per group. *P 
	< 0.05 compared with vehicle control.
Fig. 3. Prolonged (5-day) infusions of clonidine (CLN) produce sensory hypersensitivity. (A  ) Production of thermal hypersensitivity by subcutaneous clonidine. (B  ) Production of tactile hypersensitivity by subcutaneous clonidine. (C  ) Production of thermal hypersensitivity by intrathecal clonidine. (D  ) Production of tactile hypersensitivity by intrathecal clonidine. Coinfusion of the α2-adrenoreceptor–selective antagonist idazoxan (IDAZ) prevented the production of thermal and tactile hypersensitivity. Where tested, the N  -methyl-d-aspartate receptor antagonist MK-801 prevented the production of sensory hypersensitivity. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control.
×
Continuous intrathecal infusion of clonidine (30 nm/h) resulted in thermal hypersensitivity 1 day after initiation of the infusion (fig. 3C) and tactile hypersensitivity 2 days after initiation of infusion (fig. 3D). This sensory hypersensitivity was completely prevented by coinfusion of idazoxan (200 μg/h intrathecal) or MK-801 (0.7 μg/h intrathecal) through a second minipump and intrathecal catheter.
After 5 days of intrathecal clonidine infusion, content of dynorphin A (1–17) in dorsal lumbar spinal cord was increased twofold compared with vehicle (saline)–treated animals (fig. 4).
Fig. 4. Intrathecal clonidine (CLN) infusion increases dynorphin content in dorsal spinal cord. Spinal dynorphin content was measured after 5 days of clonidine infusion. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control.
Fig. 4. Intrathecal clonidine (CLN) infusion increases dynorphin content in dorsal spinal cord. Spinal dynorphin content was measured after 5 days of clonidine infusion. Data are expressed as mean ± SEM; n = 6 per group. *P 
	< 0.05 compared with vehicle control.
Fig. 4. Intrathecal clonidine (CLN) infusion increases dynorphin content in dorsal spinal cord. Spinal dynorphin content was measured after 5 days of clonidine infusion. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control.
×
Intrathecal MK-801 (3.4 μg) or intrathecal dynorphin antiserum (200 μg) administered after 5 days of clonidine infusion reversed the thermal and tactile hypersensitivity produced by continuous infusion of intrathecal clonidine (30 nm/h) (fig. 5).
Fig. 5. Intrathecal MK-801 or dynorphin antiserum (dynA/S) reverse the thermal (A  ) and tactile (B  ) hypersensitivity produced by a prolonged (5-day) infusion of intrathecal clonidine (CLN). Drugs were administered after 5 days of clonidine infusion. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control. #P  < 0.05 compared with clonidine alone.
Fig. 5. Intrathecal MK-801 or dynorphin antiserum (dynA/S) reverse the thermal (A 
	) and tactile (B 
	) hypersensitivity produced by a prolonged (5-day) infusion of intrathecal clonidine (CLN). Drugs were administered after 5 days of clonidine infusion. Data are expressed as mean ± SEM; n = 6 per group. *P 
	< 0.05 compared with vehicle control. #P 
	< 0.05 compared with clonidine alone.
Fig. 5. Intrathecal MK-801 or dynorphin antiserum (dynA/S) reverse the thermal (A  ) and tactile (B  ) hypersensitivity produced by a prolonged (5-day) infusion of intrathecal clonidine (CLN). Drugs were administered after 5 days of clonidine infusion. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control. #P  < 0.05 compared with clonidine alone.
×
Discussion
α2-Adrenoreceptor–selective agonists produce paradoxical sensory hypersensitivity. Acute administration of α2agonists results in antinociception to thermal stimuli followed by delayed sensory hypersensitivity. These results suggest that α2-adrenoreceptor–selective agonists activate not only antinociceptive systems, but also pronociceptive systems with longer activity. Continuous administration of α2agonists produces sensory hypersensitivity that is observed even during α2-agonist infusion, showing that this sensory hypersensitivity is not the result of a drug withdrawal syndrome.
Clonidine-induced sensory hypersensitivity is prevented by coadministration of the α2-adrenoreceptor–selective antagonist idazoxan, demonstrating that it is mediated by α2adrenoreceptors. Dexmedetomidine, a more selective α2-adrenoreceptor agonist, also produced thermal hypersensitivity after intrathecal administration, providing further support for the concept that activation of α2receptors is sufficient to produce delayed sensory hypersensitivity.
These experiments used high doses of α2-receptor–selective agonists. Typically, these were selected from published articles as the highest doses that were used to study antinociception or drug tolerance. This was done to maximize the likelihood of detecting α2-agonist–induced sensory hypersensitivity. This raises the question of whether similar effects would be observed at the doses of α2-receptor–selective agonists that are used for pain relief in humans. This issue is difficult to address directly in animals because of species differences in drug potency. However, in preliminary experiments, doses much smaller than those used here (for example, a clonidine infusion of 0.03 nmol/h) seem to result in sensory hypersensitivity (unpublished data, January 2004, M. Higashi, M.D., and T. P. Malan, Jr., Ph.D., M.D., Tucson, Arizona). The use of high doses of clonidine also raises the question of whether some of the effects seen may have been due to cross-reactivity at α1adrenoreceptors. However, this is unlikely because the effects of clonidine were completely prevented by idazoxan, an α2-receptor–selective antagonist.
Qualitatively, these effects seem similar to the paradoxical increase in pain sensitivity produced by opioid receptor agonists. Acute administration of opioid receptor agonists produces delayed sensory hypersensitivity after resolution of opioid antinociceptive effects. Laulin et al.  11 showed that a single subcutaneous injection of heroin resulted in an antinociceptive phase followed by a decreased response threshold to mechanical stimuli. Similar results were obtained using four injections of fentanyl at 15-min intervals. 12 Sensory hypersensitivity is also observed during prolonged opioid administration. Repeated morphine or heroin administration results in sensory hypersensitivity. 6,13 Importantly, sustained opioid administration also results in tactile and thermal hypersensitivity, indicating that this hypersensitivity is not due to intermittent drug withdrawal. 14–16 
The duration of the sensory hypersensitivity produced by acute administration of α2-adrenoreceptor agonists (a few hours) was significantly less than the reported duration of the sensory hypersensitivity produced by acute administration of opioids (days). 12,17 It is not clear whether this difference in duration reflects significant differences in the effects of the two drug classes, differences in the relative doses of drugs used, or other differences in experimental methods. The magnitude of sensory hypersensitivity after acute bolus administration of clonidine cannot be compared to the magnitude of the sensory hypersensitivity produced by acute administration of opioids in published studies, 12,17 because different measures of sensory sensitivity were used. However, the magnitude of sensory hypersensitivity produced by a 5-day infusion of clonidine in our studies is similar to the magnitude of sensory hypersensitivity produced by prolonged administration of opioids in published work in which identical sensory testing methods were used. 14 
Dynorphin content in the dorsal spinal cord is increased after a 5-day intrathecal infusion of clonidine, and clonidine-induced sensory hypersensitivity is inhibited by sequestration of dynorphin using intrathecal administration of an antiserum to dynorphin, suggesting that actions of spinal dynorphin are required for clonidine-induced sensory hypersensitivity. In addition, clonidine-induced sensory hypersensitivity is inhibited by N  -methyl-d-aspartate receptor antagonists. Interestingly, when administered during sustained intrathecal clonidine infusion, dynorphin antiserum and MK-801 prolong thermal withdrawal latency beyond preinfusion baseline values, perhaps by unmasking the antinociceptive effects of clonidine. These findings are identical to observations in studies of opioid-induced sensory hypersensitivity, 12–14,18,19 suggesting that the same mechanisms may be responsible for both phenomena. Opioid-induced sensory hypersensitivity seems to be mediated by N  -methyl-d-aspartate receptors and by actions of protein kinase C. 12,13,18,19 It may also be mediated by systems-level mechanisms. Published data suggest that sustained morphine administration activates descending facilitation from the rostral ventromedial medulla, 15 leading to an increase in spinal dynorphin expression, 14,20 which in turn leads to increased excitatory neurotransmitter release from the spinal terminals of primary afferent fibers, 21 and the facilitation of spinal transmission of pain signals.
When administered acutely, opioid receptor agonists have been reported to increase pain sensitivity in healthy volunteers 22 and to increase postoperative pain and opioid requirements in surgical patients, 23,24 although contrasting results have also been reported. 25 In addition, high-dose long-term perispinal morphine administration was associated with paradoxical hyperalgesia, allodynia, or both in a review of 750 patients, 26 and case reports have described new pains differing in character or location from the pain precipitating treatment in patients receiving perispinal opioids. 27–29 Finally, increased sensory sensitivity has also been noted in patients with opioid addiction who were receiving long-term opioid maintenance therapy. 30,31 
In contrast, paradoxical pain has not been reported in patients being treated systemically or perispinally with α2-adrenoreceptor agonists. There are several reasons why such pain may not have been reported, even if it exists. First, α2-receptor agonist–induced sensory hypersensitivity has not been systematically tested in patients. Second, fewer patients have received intrathecal clonidine than have received intrathecal morphine, making the spontaneous detection of a rare event less likely. Third, intrathecal clonidine is often administered in combination with intrathecal opioids. Because opioid-induced paradoxical pain is well recognized, any α2-receptor agonist–induced hyperalgesia may have been attributed by the treating physician to the spinal opioid and not reported. Finally, because until now there have been no preclinical data describing the production of paradoxical pain by α2-adrenorecptor agonists, clinicians may not have been looking for it in their patients. Large doses of intrathecal morphine have been known since 1981 to produce a paradoxical increase in sensory sensitivity in animals. 32 
In conclusion, physicians should be mindful of the possibility that α2-adrenoreceptor agonists might produce paradoxical pain in the same way that administration of opioid receptor agonists sometimes does. The clinical correlate of an increase in thermal sensitivity is not clear; however, tactile hypersensitivity (tactile allodynia) has been noted in patients with opioid-induced hyperalgesia. An α2-adrenoreceptor agonist–induced increase in pain sensitivity might worsen existing pains, cause new pains, or interfere with the analgesic effectiveness of α2-receptor agonists or other drugs used for pain treatment. These considerations might suggest that we should stop using α2-adrenoreceptor agonists for pain therapy. However, it would be unfortunate to prematurely discontinue this use of α2agonists, because our options for treating pain are limited and because opioid receptor agonists, the most important drugs used for the treatment of moderate-to-severe pain, produce a similar paradoxical increase in sensory hypersensitivity. A more prudent approach would be to develop ways of reversing analgesic drug–induced sensory hypersensitivity, such as combining these drugs with N  -methyl-d-aspartate receptor antagonists or with novel drugs that inhibit other steps in the pathways leading to sensory hypersensitivity. Therefore, it is important that we understand the potential for these drugs to produce paradoxical pain, study the mechanisms behind such pains, and develop means to limit the production of α2-receptor agonist–induced paradoxical pain.
References
Khan ZP, Ferguson CN, Jones RM: Alpha-2 and imidazoline receptor agonists. Anaesthesia 1999; 54:146–65
Kamibayashi T, Maze M: Clinical uses of α2adrenergic agonists. Anesthesiology 2000; 93:1345–9
Stevens CW, Monasky MS, Yaksh TL: Spinal infusion of opiate and alpha-2 agonists in rats: Tolerance and cross-tolerance studies. J Pharmacol Exp Ther 1988; 244:63–70
Takano Y, Yaksh TL: Chronic spinal infusion of dexmedetomidine ST-91 and clonidine: Spinal alpha 2 adrenoreceptor subtypes and intrinsic activity. J Pharmacol Exp Ther 1993; 264:327–35
Hayashi Y, Guo TZ, Maze M: Desensitization to the behavioral effects of α2-adrenergic agonists in rats. Anesthesiology 1995; 82:954–62
Laulin J-P, Célèrier E, Larcher A, Le Moal M, Simonnet G: Opiate tolerance to daily heroin administration: An apparent phenomenon associated with enhanced pain sensitivity. Neuroscience 1999; 89:631–6
Ossipov MH, Lai J, Vanderah TW, Porreca F: Induction of pain facilitation by sustained opioid exposure: Relationship to opioid antinociceptive tolerance. Life Sci 2003; 73:783–800
Yaksh TL, Rudy TA: Chronic catheterization of the spinal sub-arachnoid space. Physiol Biochem Behav 1976; 17:1031–6
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55–63
Hargreaves KM, Dubner R, Brown F, Flores C, Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988; 32:77–88
Laulin J-P, Larcher A, Célèrier E, Le Moal M, Simonnet G: Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur J Neurosci 1998; 10:782–5
Célèrier E, Rivat C, Jun Y, Laulin J-P, Larcher A, Reynier P, Simmonet G: Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effect of ketamine. Anesthesiology 2000; 92:465–72
Mao J, Price DD, Mayer DJ: Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994; 14:2301–12
Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, Zhang ET, Malan TP, Porreca F: Dynorphin promotes abnormal pain and opioid antinociceptive tolerance. J Neurosci 2000; 7074–9
Vanderah TW, Suenga NM, Ossipov MH, Malan TP, Lai J, Porreca F: Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci 2001; 21: 279–86
Vanderah TW, Ossipov MH, Lai J, Malan TP, Porreca F: Mechanisms of opioid-induced pain and antinociceptive tolerance: Descending facilitation and spinal dynorphin. Pain 2001; 92:5–9
Célèrier E, Laulin J-P, Corcuff J-B, Le Moal, Simonnet G: Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: A sensitization process. J Neurosci 2001; 21:4074–80
Célèrier E, Laulin J, Larcher A, Le Moal M, Simonnet G: Evidence for opiate-activated NMDA processes making opiate analgesia in rats. Brain Res 1999; 847:18–25
Laulin J-P, Maurette P, Corcuff J-B, Rivat C, Chauvin M, Simonnet G: The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg 2002; 92:1263–9
Gardell LR, Wang Z, Ossipov MH, Malan TP, Lai J, Porreca F: Lack of opioid tolerance in prodynorphin “knockout” mice. Soc Neurosci Abstr 2001; 27:616.8
Gardell LR, Wang R, Burgess S, Ossipov M, Vanderan TW, Malan TP, Lai J, Porreca F: Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002; 22:6747–55
Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schuttler J: Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S  -ketamine and clonidine in humans. Anesthesiology 2003; 99:152–9
Chia YY, Liu K, Wang JJ, Kuo MC, Ho ST: Intraoperative high dose fentanyl induces postoperative fentanyl tolerance. Can J Anaesth 1999; 46:872–7
Guignard B, Bossard AE, Coste C, Sessler DI, Lebrault C, Alofnsi P, Fletcher D, Chauvin M: Acute opioid tolerance: Intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000; 93:409–17
Cortinez L, I, Brandes V, Munoz HR, Guerrero ME, Mur M: No clinical evidence of acute opioid tolerance after remifentanil-based anesthesia. Br J Anaesth 2001; 87:866–9
Arner S, Rawal N, Gustafsson LL: Clinical experience of long-term treatment with epidural and intrathecal opioids: A nationwide survey. Acta Anaesthesiol Scand 1988; 32:253–9
Ali NM: Hyperalgesic response in a patient receiving high concentrations of spinal morphine (letter). Anesthesiology 1986;65:449
Devulder J: Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol 1997; 9:146–8
De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V: Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991; 47:337–9
Ho A, Dole VP: Pain perception in drug-free and in methadone-maintained human ex-addicts. Proc Soc Exp Biol Med 1979;16:392–5
Compton P, Charuvastra VC, Kintaudi K, Ling W: Pain responses in methadone-maintained opioid abusers. J Pain Sympt Manag 2000;20:237–45
Woolf CJ: Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Res 1981;209:491–5
Fig. 1. A single dose of α2-adrenoreceptor–selective agonist produces antinociception followed by sensory hypersensitivity. (A  ) Antinociception and thermal hypersensitivity produced by systemic (subcutaneous) clonidine (CLN). (B  ) Tactile hypersensitivity produced by systemic subcutaneous clonidine. (C  ) Antinociception and thermal hypersensitivity produced by spinal (intrathecal) clonidine. (D  ) Antinociception and thermal hypersensitivity produced by intrathecal dexmedetomidine (DEX). Where tested, the α2-adrenoreceptor–selective antagonist idazoxan (IDAZ) prevented the production of antinociception and thermal hypersensitivity. Where tested, the N  -methyl-d-aspartate receptor antagonist MK-801 prevented the production of thermal hypersensitivity. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control.
Fig. 1. A single dose of α2-adrenoreceptor–selective agonist produces antinociception followed by sensory hypersensitivity. (A 
	) Antinociception and thermal hypersensitivity produced by systemic (subcutaneous) clonidine (CLN). (B 
	) Tactile hypersensitivity produced by systemic subcutaneous clonidine. (C 
	) Antinociception and thermal hypersensitivity produced by spinal (intrathecal) clonidine. (D 
	) Antinociception and thermal hypersensitivity produced by intrathecal dexmedetomidine (DEX). Where tested, the α2-adrenoreceptor–selective antagonist idazoxan (IDAZ) prevented the production of antinociception and thermal hypersensitivity. Where tested, the N 
	-methyl-d-aspartate receptor antagonist MK-801 prevented the production of thermal hypersensitivity. Data are expressed as mean ± SEM; n = 6 per group. *P 
	< 0.05 compared with vehicle control.
Fig. 1. A single dose of α2-adrenoreceptor–selective agonist produces antinociception followed by sensory hypersensitivity. (A  ) Antinociception and thermal hypersensitivity produced by systemic (subcutaneous) clonidine (CLN). (B  ) Tactile hypersensitivity produced by systemic subcutaneous clonidine. (C  ) Antinociception and thermal hypersensitivity produced by spinal (intrathecal) clonidine. (D  ) Antinociception and thermal hypersensitivity produced by intrathecal dexmedetomidine (DEX). Where tested, the α2-adrenoreceptor–selective antagonist idazoxan (IDAZ) prevented the production of antinociception and thermal hypersensitivity. Where tested, the N  -methyl-d-aspartate receptor antagonist MK-801 prevented the production of thermal hypersensitivity. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control.
×
Fig. 2. Intrathecal MK-801 reverses the thermal hypersensitivity produced by a single dose of intrathecal clonidine (CLN). MK-801 was administered 24 h after clonidine. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control. #P  < 0.05 compared with clonidine alone.
Fig. 2. Intrathecal MK-801 reverses the thermal hypersensitivity produced by a single dose of intrathecal clonidine (CLN). MK-801 was administered 24 h after clonidine. Data are expressed as mean ± SEM; n = 6 per group. *P 
	< 0.05 compared with vehicle control. #P 
	< 0.05 compared with clonidine alone.
Fig. 2. Intrathecal MK-801 reverses the thermal hypersensitivity produced by a single dose of intrathecal clonidine (CLN). MK-801 was administered 24 h after clonidine. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control. #P  < 0.05 compared with clonidine alone.
×
Fig. 3. Prolonged (5-day) infusions of clonidine (CLN) produce sensory hypersensitivity. (A  ) Production of thermal hypersensitivity by subcutaneous clonidine. (B  ) Production of tactile hypersensitivity by subcutaneous clonidine. (C  ) Production of thermal hypersensitivity by intrathecal clonidine. (D  ) Production of tactile hypersensitivity by intrathecal clonidine. Coinfusion of the α2-adrenoreceptor–selective antagonist idazoxan (IDAZ) prevented the production of thermal and tactile hypersensitivity. Where tested, the N  -methyl-d-aspartate receptor antagonist MK-801 prevented the production of sensory hypersensitivity. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control.
Fig. 3. Prolonged (5-day) infusions of clonidine (CLN) produce sensory hypersensitivity. (A 
	) Production of thermal hypersensitivity by subcutaneous clonidine. (B 
	) Production of tactile hypersensitivity by subcutaneous clonidine. (C 
	) Production of thermal hypersensitivity by intrathecal clonidine. (D 
	) Production of tactile hypersensitivity by intrathecal clonidine. Coinfusion of the α2-adrenoreceptor–selective antagonist idazoxan (IDAZ) prevented the production of thermal and tactile hypersensitivity. Where tested, the N 
	-methyl-d-aspartate receptor antagonist MK-801 prevented the production of sensory hypersensitivity. Data are expressed as mean ± SEM; n = 6 per group. *P 
	< 0.05 compared with vehicle control.
Fig. 3. Prolonged (5-day) infusions of clonidine (CLN) produce sensory hypersensitivity. (A  ) Production of thermal hypersensitivity by subcutaneous clonidine. (B  ) Production of tactile hypersensitivity by subcutaneous clonidine. (C  ) Production of thermal hypersensitivity by intrathecal clonidine. (D  ) Production of tactile hypersensitivity by intrathecal clonidine. Coinfusion of the α2-adrenoreceptor–selective antagonist idazoxan (IDAZ) prevented the production of thermal and tactile hypersensitivity. Where tested, the N  -methyl-d-aspartate receptor antagonist MK-801 prevented the production of sensory hypersensitivity. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control.
×
Fig. 4. Intrathecal clonidine (CLN) infusion increases dynorphin content in dorsal spinal cord. Spinal dynorphin content was measured after 5 days of clonidine infusion. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control.
Fig. 4. Intrathecal clonidine (CLN) infusion increases dynorphin content in dorsal spinal cord. Spinal dynorphin content was measured after 5 days of clonidine infusion. Data are expressed as mean ± SEM; n = 6 per group. *P 
	< 0.05 compared with vehicle control.
Fig. 4. Intrathecal clonidine (CLN) infusion increases dynorphin content in dorsal spinal cord. Spinal dynorphin content was measured after 5 days of clonidine infusion. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control.
×
Fig. 5. Intrathecal MK-801 or dynorphin antiserum (dynA/S) reverse the thermal (A  ) and tactile (B  ) hypersensitivity produced by a prolonged (5-day) infusion of intrathecal clonidine (CLN). Drugs were administered after 5 days of clonidine infusion. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control. #P  < 0.05 compared with clonidine alone.
Fig. 5. Intrathecal MK-801 or dynorphin antiserum (dynA/S) reverse the thermal (A 
	) and tactile (B 
	) hypersensitivity produced by a prolonged (5-day) infusion of intrathecal clonidine (CLN). Drugs were administered after 5 days of clonidine infusion. Data are expressed as mean ± SEM; n = 6 per group. *P 
	< 0.05 compared with vehicle control. #P 
	< 0.05 compared with clonidine alone.
Fig. 5. Intrathecal MK-801 or dynorphin antiserum (dynA/S) reverse the thermal (A  ) and tactile (B  ) hypersensitivity produced by a prolonged (5-day) infusion of intrathecal clonidine (CLN). Drugs were administered after 5 days of clonidine infusion. Data are expressed as mean ± SEM; n = 6 per group. *P  < 0.05 compared with vehicle control. #P  < 0.05 compared with clonidine alone.
×